T1	Participants 115 123	melanoma
T2	Participants 134 186	Nearly 2000 patients with stage IIB and III melanoma
T3	Participants 697 739	patients in E1684, E1690, E1694, and E2696
T4	Participants 819 831	713 patients
T5	Participants 1430 1509	ulceration, recurrent disease at entry, enrollment in E1684, and age > 49 years
T6	Participants 1732 1773	patients with high-risk resected melanoma
